Horizon Pharma Inc. (NASDAQ:HZNP) Receives Average Rating of “Buy” from Analysts
Shares of Horizon Pharma Inc. (NASDAQ:HZNP) have earned a consensus rating of “Buy” from the sixteen brokerages that are covering the company. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $31.56.
A number of research firms have recently issued reports on HZNP. Vetr raised Horizon Pharma from a “buy” rating to a “strong-buy” rating and set a $21.00 price objective for the company in a research report on Monday, June 13th. BMO Capital Markets began coverage on Horizon Pharma in a research report on Tuesday, June 28th. They issued an “outperform” rating and a $29.00 price objective for the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $45.00 price objective on shares of Horizon Pharma in a research report on Wednesday, July 6th. Morgan Stanley raised Horizon Pharma from an “underweight” rating to an “equal weight” rating and set a $24.00 price objective for the company in a research report on Monday, July 11th. Finally, Zacks Investment Research raised Horizon Pharma from a “hold” rating to a “buy” rating and set a $21.00 price objective for the company in a research report on Monday, July 11th.
Horizon Pharma (NASDAQ:HZNP) traded down 1.767% during mid-day trading on Friday, hitting $18.625. The stock had a trading volume of 809,945 shares. The firm’s market capitalization is $3.00 billion. Horizon Pharma has a one year low of $12.86 and a one year high of $23.70. The stock’s 50 day moving average price is $19.27 and its 200 day moving average price is $17.78.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/horizon-pharma-inc-nasdaqhznp-receives-average-rating-of-buy-from-analysts.html
Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.50 by $0.12. Horizon Pharma had a positive return on equity of 23.46% and a negative net margin of 0.34%. The firm earned $257.40 million during the quarter, compared to analysts’ expectations of $235.43 million. During the same period in the prior year, the firm posted $0.39 earnings per share. The business’s quarterly revenue was up 48.9% compared to the same quarter last year. Analysts forecast that Horizon Pharma will post $2.15 EPS for the current year.
In other Horizon Pharma news, EVP Jeffrey W. Sherman sold 2,900 shares of the firm’s stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $20.00, for a total transaction of $58,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 2.10% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Virginia Retirement System acquired a new stake in shares of Horizon Pharma during the first quarter worth $282,000. Algert Global LLC increased its stake in shares of Horizon Pharma by 57.3% in the first quarter. Algert Global LLC now owns 20,872 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 7,602 shares in the last quarter. Franklin Resources Inc. increased its stake in shares of Horizon Pharma by 5,195.9% in the first quarter. Franklin Resources Inc. now owns 1,276,730 shares of the biopharmaceutical company’s stock worth $21,155,000 after buying an additional 1,252,622 shares in the last quarter. BlackRock Group LTD increased its stake in shares of Horizon Pharma by 21.0% in the first quarter. BlackRock Group LTD now owns 100,919 shares of the biopharmaceutical company’s stock worth $1,672,000 after buying an additional 17,505 shares in the last quarter. Finally, BlackRock Fund Advisors increased its stake in shares of Horizon Pharma by 7.6% in the first quarter. BlackRock Fund Advisors now owns 2,937,687 shares of the biopharmaceutical company’s stock worth $48,677,000 after buying an additional 208,391 shares in the last quarter. Hedge funds and other institutional investors own 85.25% of the company’s stock.
Horizon Pharma Company Profile
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.